In a recent conversation with James Feliciano, former president of AbbVie Japan, we delved into the intricacies of leadership in the Japanese pharmaceutical industry. Feliciano, a seasoned industry veteran, shared valuable insights into his experiences, challenges, and successes.Navigating the Abbott…
BUSINESS
Life Science Institute Begins Muse Cell Trial for Spinal Injury; President Confident of Profitability
Life Science Institute, a Mitsubishi Chemical Group company, said on July 9 that it has launched a clinical trial in Japan for its multi-lineage differentiating stress enduring (Muse) cell therapy CL2020 to treat patients with spinal cord injuries - the…
To read the full story
Related Article
- Life Science Institute to Establish New Field of Reparative Medicine with Muse Cells: President
May 20, 2021
- Life Science Institute to Begin Exploratory Study of Muse Cell Therapy for COVID-19-Associated ARDS
April 21, 2021
- Life Science Institute to Test Muse Cell Therapy in ALS
January 29, 2021
- Life Science Institute’s Muse Cell Therapy Effective in Epidermolysis Bullosa
July 30, 2020
- Life Science Institute’s Muse Cell Product Shows Safety, Tolerability in 2 Trials
April 24, 2020
- Life Science Institute’s Muse Cell Product Processing Facility Bags Manufacturing License
August 8, 2019
- Life Science Institute Initiates Exploratory Clinical Trial of Muse Cell Product for Epidermolysis Bullosa
December 21, 2018
- Life Science Institute to Initiate Exploratory Clinical Study of Muse Cell Product for Cerebral Infarction
September 4, 2018
- Life Science Institute Launches Clinical Study of IV Regenerative Medicine Product for Acute Myocardial Infarction
January 18, 2018
BUSINESS
- Nippon Shinyaku’s Viltepso Patents Invalid: US Jury Verdict
December 24, 2024
- Increased Off-Year Pressure on LLPs Would Only Exacerbate Supply Crunch: Industry Officials
December 24, 2024
- Eisai/Fujirebio Tie Up in Biomarker Research for Neurodegenerative Diseases
December 24, 2024
- Orion Now MA Holder of Parkinson’s Meds Stalevo, Comtan in Japan
December 24, 2024
- Shionogi to Take Full Control of 2 China Joint Ventures
December 24, 2024
The Ministry of Health, Labor and Welfare (MHLW) on December 18 presented a proposal to define the scope of products…
Eli Lilly’s Kisunla (donanemab) will join the Japanese reimbursement list on November 20, with a health ministry panel giving the…
Will an “off-year” drug price revision happen in April 2025 or not? Over the last week, expectations have been up…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…